Hemoadsorption for Cardiac Surgery Patients
Efferon LPS Hemoadsorption in Cardiac Surgery Patients
Recruiting
N/A
Interventional Study
Cardiac Disease
Multiple Organ Dysfunction Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Efferon JSC · Industry
Who this trial is looking for
This trial is looking for patients who are having heart surgery that requires a heart-lung machine. If I take part, I will receive two treatments to help reduce complications related to my organs after surgery.
Are You a Good Fit for This Trial?
You may be able to join if
- I am an adult
- I am undergoing cardiac surgery with a heart-lung machine
- My EuroSCORE II is 6% or higher
You may not be able to join if
- My procalcitonin level is 2 ng/mL or higher
- I have severe chronic liver disease
- I am dependent on dialysis
- I am taking immunosuppressive therapy
- The doctor thinks I should not participate in this study
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass in reducing the incidence and severity of multiple organ dysfunction syndrome (MODS) in the postoperative period. Each patient in the treatment group will undergo two hemoa…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients undergoing elective or emergency cardiac surgery with the use of cardiopulmonary bypass (CPB).
* EuroSCORE II ≥6%
Exclusion Criteria:
* Procalcitonin ≥2 ng/mL
* Severe chronic liver disease, defined as Child-Pugh class C (\>10 points) or clinically manifest he…
Contacts